Status:
COMPLETED
Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
IgG4 Related Disease
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
Since December 2019, coronavirus disease 2019 (COVID-19), caused by the severe respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than 124 million people worldwide as of 23/3/2021. Whi...
Detailed Description
Since December 2019, coronavirus disease 2019 (COVID-19), caused by the severe respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than 124 million people worldwide as of 23/3/2021. Whi...
Eligibility Criteria
Inclusion
- Age 18 or above
- IgG4 related disease patients with pancreatobiliary involvement receiving care in the GI clinic of the participating centers
- The diagnosis of IgG4 related disease was made either by:
- an elevated serum IgG4 serology level with typical features of pancreatobiliary involvement on imaging (eg, CT / MRI), and/or endoscopic ultrasound (EUS), and/or endoscopic retrograde cholangiopancreatography (ERCP), or
- an elevated serum IgG4 serology level with typical histopathologic features of the disease (eg, lymphoplasmacytic infiltration, obliterative phlebitis, and storiform fibrosis) on surgical pathology (eg, biopsy during surgery or surgical resection specimen) or endoscopic biopsies (eg, EUS guided fine needle biopsy).
Exclusion
- 1\) Patients who have an alternative diagnosis (i.e., non-IgG4 disease) despite an elevated serum IgG4 level
Key Trial Info
Start Date :
March 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 10 2023
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT04817553
Start Date
March 24 2021
End Date
January 10 2023
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital, The Chinese University of Hong Kong
Shatin, New Territories, Hong Kong